The present invention discloses a combination of digestive enzymes (Protease, Amylase, Lactase, Lipase, Cellulase)DigeZyme for the therapeutic management of delayed onset muscle soreness (DOMS)

Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.

The present invention relates to methods of reducing, delaying, preventing and/or inhibiting the progression of a Cryptococcus infection into the central nervous system (CNS) of a subject by inhibiting the activity of a M36 fungalysin metalloprotease (e.g., MPR1) secreted by the Cryptococcus. The invention further provides methods of increasing, promoting and/or enhancing delivery of a therapeutic agent across the blood-brain-barrier, comprising systemically administering the therapeutic agent in conjunction with a M36 fungalysin metalloprotease (e.g., MPR1), or an enzymatically active fragment thereof.

Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.

The present disclosure discloses a composition for skin anti-aging, skin lightening, or skin texture improvement containing a metalloproteinase derived from a strain of the genus Chryseobacterium as an active ingredient, and/or a composition for inhibition of lipofuscin accumulation or for removal of lipofuscin containing the metalloproteinase as an active ingredient. The composition provides an efficacy of skin anti-aging, skin lightening, or skin texture improvement by inhibition of lipofuscin accumulation or by removal of lipofuscin, and provides an effect of preventing, improving, or treating a disease caused by lipofuscin accumulation.